CoChat

EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors

Open access
Li, Dan, Guo, Xianling, Yang, Kun, Yang, Yuening, Zhou, Weilin, Huang, Yong, Liang, Xiao, Su, Jinhua, Jiang, Lin, Li, Jing, Fu, Maorong, He, Haixia, Yang, Jinrong, Shi, Huashan, Yang, Hanshuo, Tong, Aiping, Chen, Nianyong, Hu, Jiankun, Xu, Qing, Wei, Yu-Quan, Wang, Wei · 2023 · Science Advances

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM–CAR-T cells for solid tumors. We demonstrated that EpCAM–CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice. Notably, in clinical trials for epithelial tumors (NCT02915445), 6 (50%) of the 12 enrolled patients experienced self-remitted grade 1/2 toxicities, 1 patient (8.3%) experienced reversible grade 3 leukopenia, and no higher-grade toxicity reported. Efficacy analysis determined two patients as partial response. Three patients showed >23 months of progression-free survival, among whom one patient experienced 2-year progress-free survival with detectable CAR-T cells 200 days after infusion. These data demonstrate the feasibility and tolerability of EpCAM–CAR-T therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.adg9721

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. The Dectin-1–stimulated EpCAM-specific CAR has a distinct effect on T cell in self-activation, differentiation, and exhaustion compared with that of CARs with the CD28 or 4-1BB costimulatory domain. (A) Schematic of EpCAM-specific CARs carrying CD28, 4-1BB, or Dectin-1 costimulatory domain. (B) Expression of different EpCAM-specific CARs on T cells, respectively. (C and D) Expression of activation-related markers on CAR-T cells after 9 days of CAR transduction. n = 5 different donors. Cells were pregated for the CD3+CAR+ subset. (E) Expression of exhaustion-associated receptors on CAR-T cells after 9 days of lentivirus transduction. The color lines are represented as mean. (F) Fold change of EpCAM–CAR-T cells differentiation in central memory and effector phenotypes of five different donors. The data are displayed as mean. (G) Schematic of the xenograft model. B-NDG mice were intraperitoneally injected with 2 × 105 HT-29–Luc cells on day −7. After that, the mice were intraperitoneally infused with three doses of Mock-T or CAR-T cells. n = 6 mice for each group. After 21 days of tumor inoculation, mice were euthanized to analyze CAR-T cell persistence. (H and I) Bioluminescence images and statistical results of tumor burden. (J and K) The percent of splenetic Mock-T cells and CAR-T cells after 21 days of adoptive T cell therapy. (L) Differentiation of splenetic CD4+ and CD8+ CAR-T cells in central memory and effector phenotypes in the xenograft model. (M and N) Exhaustion-associated receptors expression on splenetic CAR-T cells after 21 days of adoptively T cells administration. The data are presented as mean ± SD. *P < 0.05 and **P < 0.01. P < 0.05 was considered statistically significant. ns, no significance. Wilcoxon test was used for (D) to (F). Two-tailed unpaired Student’s t test was used for differences analysis in (K), (L), and (N). TM, transmembrane domain; Teff, effector T cell; Tcm, central memory T cells.
Fig. 1. The Dectin-1–stimulated EpCAM-specific CAR has a distinct effect on T cell in self-activation, differentiation, and exhaustion compared with that of CARs with the CD28 or 4-1BB costimulatory domain. (A) Schematic of EpCAM-specific CARs carrying CD28, 4-1BB, or Dectin-1 costimulatory domain. (B) Expression of different EpCAM-specific CARs on T cells, respectively. (C and D) Expression of activation-related markers on CAR-T cells after 9 days of CAR transduction. n = 5 different donors. Cells were pregated for the CD3+CAR+ subset. (E) Expression of exhaustion-associated receptors on CAR-T cells after 9 days of lentivirus transduction. The color lines are represented as mean. (F) Fold change of EpCAM–CAR-T cells differentiation in central memory and effector phenotypes of five different donors. The data are displayed as mean. (G) Schematic of the xenograft model. B-NDG mice were intraperitoneally injected with 2 × 105 HT-29–Luc cells on day −7. After that, the mice were intraperitoneally infused with three doses of Mock-T or CAR-T cells. n = 6 mice for each group. After 21 days of tumor inoculation, mice were euthanized to analyze CAR-T cell persistence. (H and I) Bioluminescence images and statistical results of tumor burden. (J and K) The percent of splenetic Mock-T cells and CAR-T cells after 21 days of adoptive T cell therapy. (L) Differentiation of splenetic CD4+ and CD8+ CAR-T cells in central memory and effector phenotypes in the xenograft model. (M and N) Exhaustion-associated receptors expression on splenetic CAR-T cells after 21 days of adoptively T cells administration. The data are presented as mean ± SD. *P < 0.05 and **P < 0.01. P < 0.05 was considered statistically significant. ns, no significance. Wilcoxon test was used for (D) to (F). Two-tailed unpaired Student’s t test was used for differences analysis in (K), (L), and (N). TM, transmembrane domain; Teff, effector T cell; Tcm, central memory T cells.CC BY-NC · PubMed Central
Fig. 2. Intraperitoneal and intravenous infusion of EpCAM–CAR-T cells induced colon cancer remission in a xenograft mouse model. (A) Schematic of the animal experiments. B-NDG mice were intraperitoneally injected with 2 × 105 Luc-expressing HT-29–Luc cells on day −7. After that, the mice were randomly assigned to different groups and were intraperitoneally or intravenously infused with three doses of Mock-T or CAR-T cells. n = 5 mice for each group. (B and C) Bioluminescence images and statistical result of tumor burden after intravenous administration of CAR-T cells. (D and E) Tumor weight at the end point of the experiment and the survival of mice who received intravenous CAR-T infusion. (F and G) Bioluminescence images and statistical result of tumor burden after intraperitoneal administration of CAR-T cells. (H and I) Tumor weight at the end point of the experiment and the survival of mice who received intraperitoneal CAR-T infusion. (J to M) Flow cytometry analysis of EpCAM–CAR-T cell persistence in the spleens of mice with intravenous (J) and (K) or intraperitoneal (L) and (M) T cell infusion. The Mock-T cell group was examined on day 21, and the CAR-T cell groups were examined when euthanized. n = 4 mice in the 1 × 107 CAR-T cells intravenously treated group and n = 5 mice in the other group. (N and O) EpCAM–CAR-T cells persisted in the peripheral blood of mice that received intravenous infusion of T cells. (P and Q) Representative results showing tumor-infiltrated human CD3+ T cells in mice that received intravenous injection of T cells, as determined by immunohistochemistry (P) and statistical results shown in (Q). Scale bars, 200 μm (white) and 50 μm (black). The data are expressed as the means ± SD. Log-rank test for (E) and (I) and Mann-Whitney U test for (C), (D), (G), (H), (K), (M), and (O). *P < 0.05, **P < 0.01, and ****P < 0.0001. P < 0.05 was considered statistically significant.
Fig. 2. Intraperitoneal and intravenous infusion of EpCAM–CAR-T cells induced colon cancer remission in a xenograft mouse model. (A) Schematic of the animal experiments. B-NDG mice were intraperitoneally injected with 2 × 105 Luc-expressing HT-29–Luc cells on day −7. After that, the mice were randomly assigned to different groups and were intraperitoneally or intravenously infused with three doses of Mock-T or CAR-T cells. n = 5 mice for each group. (B and C) Bioluminescence images and statistical result of tumor burden after intravenous administration of CAR-T cells. (D and E) Tumor weight at the end point of the experiment and the survival of mice who received intravenous CAR-T infusion. (F and G) Bioluminescence images and statistical result of tumor burden after intraperitoneal administration of CAR-T cells. (H and I) Tumor weight at the end point of the experiment and the survival of mice who received intraperitoneal CAR-T infusion. (J to M) Flow cytometry analysis of EpCAM–CAR-T cell persistence in the spleens of mice with intravenous (J) and (K) or intraperitoneal (L) and (M) T cell infusion. The Mock-T cell group was examined on day 21, and the CAR-T cell groups were examined when euthanized. n = 4 mice in the 1 × 107 CAR-T cells intravenously treated group and n = 5 mice in the other group. (N and O) EpCAM–CAR-T cells persisted in the peripheral blood of mice that received intravenous infusion of T cells. (P and Q) Representative results showing tumor-infiltrated human CD3+ T cells in mice that received intravenous injection of T cells, as determined by immunohistochemistry (P) and statistical results shown in (Q). Scale bars, 200 μm (white) and 50 μm (black). The data are expressed as the means ± SD. Log-rank test for (E) and (I) and Mann-Whitney U test for (C), (D), (G), (H), (K), (M), and (O). *P < 0.05, **P < 0.01, and ****P < 0.0001. P < 0.05 was considered statistically significant.CC BY-NC · PubMed Central
Fig. 3. EpCAM–CAR-T cells were well tolerated by EpCAM-humanized mice. (A) Genetic engineering strategy for EpCAM-humanized C57BL/6 mice. The murine EpCAM gene locus was truncated, and a homologous human EpCAM gene locus was inserted from exon 2 to exon 7. Purple, exon of mouse EpCAM; green, exon of human EpCAM; E, exon. (B) Experimental schematic showing the safety evaluation in the C57BL/6-EpCAMtml EpCAM mouse model. The mice were randomly grouped; n = 3 per group. All mice were preconditioned with cyclophosphamide (100 mg/kg). Two days later, a single dose of Mock-T cells (1 × 106) or EpCAM–CAR-T cells (1 × 106, 5 × 106, and 1 × 107) was intravenously administered. (C) Percentage of body weight change was normalized to that on day 0 after T cell infusion. (D) Serum cytokine levels in peripheral blood at the indicated points after T cell infusion (means ± SD). (E and F) Representative immunohistochemical (E) and quantitative real-time PCR (F) analysis of mouse CD3+ cells (E) and EpCAM-CAR gene (F) distribution in the spleen, lung, and other organs 7 days after T cell transfer. Scale bars, 50 μm. (G to J) Organ damage-related serum biomarkers were measured in the liver (G), kidney (H), heart (I), and pancreas (J) on day 7 after T cell transfer. The data are presented as the means ± SD, and data analysis was performed by one-way analysis of variance (ANOVA). P < 0.05 was considered statistically significant. AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRE, creatinine; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; CK-MB, creatine kinase-MB; AMY, amylase.
Fig. 3. EpCAM–CAR-T cells were well tolerated by EpCAM-humanized mice. (A) Genetic engineering strategy for EpCAM-humanized C57BL/6 mice. The murine EpCAM gene locus was truncated, and a homologous human EpCAM gene locus was inserted from exon 2 to exon 7. Purple, exon of mouse EpCAM; green, exon of human EpCAM; E, exon. (B) Experimental schematic showing the safety evaluation in the C57BL/6-EpCAMtml EpCAM mouse model. The mice were randomly grouped; n = 3 per group. All mice were preconditioned with cyclophosphamide (100 mg/kg). Two days later, a single dose of Mock-T cells (1 × 106) or EpCAM–CAR-T cells (1 × 106, 5 × 106, and 1 × 107) was intravenously administered. (C) Percentage of body weight change was normalized to that on day 0 after T cell infusion. (D) Serum cytokine levels in peripheral blood at the indicated points after T cell infusion (means ± SD). (E and F) Representative immunohistochemical (E) and quantitative real-time PCR (F) analysis of mouse CD3+ cells (E) and EpCAM-CAR gene (F) distribution in the spleen, lung, and other organs 7 days after T cell transfer. Scale bars, 50 μm. (G to J) Organ damage-related serum biomarkers were measured in the liver (G), kidney (H), heart (I), and pancreas (J) on day 7 after T cell transfer. The data are presented as the means ± SD, and data analysis was performed by one-way analysis of variance (ANOVA). P < 0.05 was considered statistically significant. AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRE, creatinine; BUN, blood urea nitrogen; LDH, lactate dehydrogenase; CK-MB, creatine kinase-MB; AMY, amylase.CC BY-NC · PubMed Central
Fig. 4. EpCAM–CAR-T cell clinical protocol design and cohort diagram. (A) Clinical protocol schematic for patient screening, CAR-T cell manufacture, and time points of the clinical study. Cy, cyclophosphamide; Flu, fludarabine; CT c/a/p, computed tomography of chest/abdomen/pelvis. (B) Number of patients screened, enrolled, and treated with autologous EpCAM–CAR-T cells in the clinical study. (C) Waterfall plot summarizing the adverse effects of CAR-T therapy in the clinical study. (D) Swimming plot showing patients’ disease development and substantial therapy and present status. IMRT, intensity-modulated radiotherapy.
Fig. 4. EpCAM–CAR-T cell clinical protocol design and cohort diagram. (A) Clinical protocol schematic for patient screening, CAR-T cell manufacture, and time points of the clinical study. Cy, cyclophosphamide; Flu, fludarabine; CT c/a/p, computed tomography of chest/abdomen/pelvis. (B) Number of patients screened, enrolled, and treated with autologous EpCAM–CAR-T cells in the clinical study. (C) Waterfall plot summarizing the adverse effects of CAR-T therapy in the clinical study. (D) Swimming plot showing patients’ disease development and substantial therapy and present status. IMRT, intensity-modulated radiotherapy.CC BY-NC · PubMed Central
Fig. 5. EpCAM–CAR-T cell persistence, cytokine secretion and radiologic evaluation of patients after EpCAM–CAR-T cell infusion. (A) EpCAM-CAR gene copies in genomic DNA of peripheral blood from patients at the indicated times following CAR-T cell transfer. (B to D) Representative serum IL-6 (B), TNF-α (C), and CRP (D) levels in patients treated with EpCAM–CAR-T cells. Cohort 1: violet; cohort 2: blue; cohort 3: orange. (E) Computed tomography scans showing the tumor response in patient 10 and patient 3 after EpCAM–CAR-T cell transfer. Red arrows indicate the tumor site.
Fig. 5. EpCAM–CAR-T cell persistence, cytokine secretion and radiologic evaluation of patients after EpCAM–CAR-T cell infusion. (A) EpCAM-CAR gene copies in genomic DNA of peripheral blood from patients at the indicated times following CAR-T cell transfer. (B to D) Representative serum IL-6 (B), TNF-α (C), and CRP (D) levels in patients treated with EpCAM–CAR-T cells. Cohort 1: violet; cohort 2: blue; cohort 3: orange. (E) Computed tomography scans showing the tumor response in patient 10 and patient 3 after EpCAM–CAR-T cell transfer. Red arrows indicate the tumor site.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 97

Metadata

Authors
Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., Fu, M., He, H., Yang, J., Shi, H., Yang, H., Tong, A., Chen, N., Hu, J., Xu, Q., Wei, Y.-Q., & Wang, W.
Affiliations
  • Sichuan University (CN)
  • Shanghai Tenth People's Hospital (CN)
  • Sun Yat-sen University (CN)
  • Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
Corresponding author
  • Li, Dan
  • Guo, Xianling
  • Yang, Kun
  • Chen, Nianyong
  • Xu, Qing
  • Wei, Yu-Quan
  • Wang, Wei
Venue
Science Advances
Published
2023-12
Volume
9
Issue
48
Pages
eadg9721-eadg9721
ISSN
2375-2548 (ISSN-L)
OpenAlex
W4389232854
Cited by
97
References
57
Citations by year
2026: 31 · 2025: 49 · 2024: 17
FWCI
11.78
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81972878, 82172733)
  • National Key Research and Development Program of China (2016YFC1303403, 2020YFC0860200)
  • Key Research and Development Program of Sichuan Province (2022ZDZX0024)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
EpCAM, CAR T-cell therapy, solid tumors, epithelial tumors, antitumor immunity, xenograft models, humanized mice, treatment toxicity, progression-free survival, tumor markers
MeSH terms
Epithelial Cell Adhesion Molecule, Receptors, Chimeric Antigen, Animals, Humans, Immunotherapy, Neoplasms, Glandular and Epithelial, T-Lymphocytes, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. https://app.cochat.ai/papers/10.1126/sciadv.adg9721
The paper
Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., Fu, M., He, H., Yang, J., Shi, H., Yang, H., Tong, A., Chen, N., Hu, J., Xu, Q., . . . Wang, W. (2023). EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors. Science Advances. https://doi.org/10.1126/sciadv.adg9721

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.